Abstract
Objective: This study was performed to test whether corticosteroids were superior to intravenous immunoglobulins (IVIG) in the treatment of neonatal autoimmune thrombocytopenia (NAT). Methods: All cases received IVIG, and unresponsive cases received corticosteroids. Results: Of 7 babies who received IVIG, only 1 responded. The 6 remaining cases received corticosteroids thereafter, and all of them responded well to this therapy. Conclusions: Corticosteroids may be more effective than IVIG in NAT.
References
1.
Cohen DL, Baglin TP: Assessment and management of immune thrombocytopenia in pregnancy and in neonates. J Br Pediatr Assoc 1995;72:71–76.
2.
Ballin A, Andrew M, Ling E, Perlman M, Blanchette V: High-dose intravenous gammaglobulin therapy for neonatal autoimmune thrombocytopenia. J Pediatr 1988;112:789–792.
3.
Andrew M: The hemostatic system in the infant; in Nathan DG, Oski FA (eds): Hematology of Infancy of Childhood. Philadelphia, Saunders, 1993, pp 125–128.
4.
Corrigan JJ: Hemorrhagic and thrombotic diseases; in Nelson WE (ed): Textbook of Pediatrics. Philadelphia, Saunders, 1996, pp 1434.
5.
Silver RM, Branch DW, Scott JR: Maternal thrombocytopenia in pregnancy: Time for a reassessment. Am J Obstet Gynecol 1995;173:479–482.
6.
Burrows RF, Kelton JG: Perinatal thrombocytopenia. Clin Perinatol 1995;22:779–801.
7.
Mazzucconi MG, Petrelli V, Gandolfo GM: Autoimmune thrombocytopenic purpura in pregnancy: Maternal risk factors predictive of neonatal thrombocytopenia. Autoimmunity 1993;16:209–214.
8.
Samuels P, Bussel JB, Braitman LE, Tomaski A, Druzin ML, Menutti MT, Cines DB: Estimation of the risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. N Engl J Med 1990;323:229–235.
9.
Christiaens GCM, Nieuwenhuis HK, VonDem Borne AE: Idiopathic thrombocytopenic purpura in pregnancy: A randomized trial on the effect of antenatal low dose corticosteroids on neonatal platelet count. Br J Obstet Gynecol 1990;97:893–898.
10.
Berchtoid P, Wenger M: Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: Their clinical significance and response to treatment. Blood 1993;81:1246–1250.
11.
Karpatkin M: Clinical and laboratory observations: Corticosteroid therapy in thrombocytopenic infants of women with autoimmune thrombocytopenia. J Pediatr 1984;105:623–625.
12.
Grosbois B, Le-Gall E, Picaud JC: Treatment of autoimmune neonatal thrombocytopenia with high-dose intravenous immunoglobulins. Ann Med Interne (Paris) 1990;141:111–114.
13.
Linder N, Shapiro SC, Moser AM, Roitman J, Engelhard D: Treatment of neonatal immune thrombocytopenia with high-dose intravenous gamma-globulin. Dev Pharmacol Ther 1990;14:205–208.
14.
Murgia S, Del- Curto E, Zecca D: The early high dose immunoglobulin treatment of neonatal autoimmune thrombocytopenia. Minerva Pediatr 1992;44:593–594.
15.
Özsoylu S, Irken G, Karabent A: High dose intravenous methylprednisolone for acute childhood idiopathic thrombocytopenic purpura. Eur J Haematol 1989;42:431.
16.
Özsoylu S, Ertürk G: Oral megadose methylprednisolone for childhood acute idiopathic thrombocytopenic purpura. Blood 1991;77:1856.
17.
Özsoylu S: Megadose methylprednisolone for childhood acute idiopathic thrombocytopenic purpura. Acta Haematol 1993;90:109.
18.
Özsoylu S, Ertürk G, Sayli RT: Oral megadose methylprednisolone versus intravenous gamma-globulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 1993;10:317.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
